Enhancing immunotherapy in triple negative breast cancer through necroptosis-mediated immune modulation

NIAID Data Ecosystem2026-05-10 收录

三阴性乳腺癌治疗

凋亡基因表达

数据链接：

https://www.ncbi.nlm.nih.gov/sra/SRP557816 数据链接链接失效反馈

官方服务：

资源简介：

RNA-Sequencing datasets accompanying the study: Enhancing immunotherapy in triple negative breast cancer through necroptosis-mediated immune modulation.

创建时间：

2026-01-29

Global transcriptome profiling of triple-negative breast cancer cell lines treated with small-molecules targeting Bromodomain and Extra Terminal (BET) proteins

三阴性乳腺癌治疗

BET蛋白调控

Triple negative breast cancer (TNBC) represents the most clinically challenging subtypes of breast cancer for which targeted therapeutics are still lacking. Bromodomain and Extra Terminal (BET) protei

NIAID Data Ecosystem40

DataSheet_1_Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer.docx

三阴性乳腺癌治疗

预测性生物标志物发现

BackgroundWe report the clinical activity, safety, and identification of a predictive biomarker for bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain o

NIAID Data Ecosystem30

Conjugates Derived from Lapatinib Derivatives with Cancer Cell Stemness Inhibitors Effectively Reversed Drug Resistance in Triple-Negative Breast Cancer

药物化学

三阴性乳腺癌治疗

Increasing evidence indicates that the cancer stem cell (CSC) subpopulation contributes to the therapeutic resistance and metastasis of tumors, leading to patient recurrence and death. Herein, we desi

acs.figshare.com2023-06-10 更新20

Cytochalasin D as a potential MAPK family inhibitor for treating triple-negative breast cancer

三阴性乳腺癌治疗

MAPK信号通路

Cytochalasin D, a potent fungal metabolite, has garnered considerable attention due to its diverse biological activities and potential pharmacological applications. Renowned for its ability to disrupt

Taylor & Francis Group2025-02-27 更新30

Data_Sheet_1_CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.docx

CAR-NKT细胞疗法

三阴性乳腺癌治疗

Antibody-derived chimeric antigen receptor (CAR) T cell therapy has achieved gratifying breakthrough in hematologic malignancies but has shown limited success in solid tumor immunotherapy. Monoclonal

NIAID Data Ecosystem20

Enhancing immunotherapy in triple negative breast cancer through necroptosis-mediated immune modulation

资源简介：

相关数据集